Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) hit a new 52-week low during trading on Thursday . The stock traded as low as $1.87 and last traded at $1.90, with a volume of 100 shares traded. The stock had previously closed at $1.99.
AZRX has been the subject of several recent research reports. Oppenheimer initiated coverage on shares of AzurRx BioPharma in a research note on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 target price for the company. HC Wainwright set a $8.00 target price on shares of AzurRx BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 16th. CIBC initiated coverage on shares of AzurRx BioPharma in a research note on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 target price for the company. Finally, ValuEngine upgraded shares of AzurRx BioPharma from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.
Several institutional investors and hedge funds have recently bought and sold shares of AZRX. Opaleye Management Inc. purchased a new position in shares of AzurRx BioPharma in the second quarter worth about $417,000. Ardsley Advisory Partners increased its stake in shares of AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock worth $440,000 after purchasing an additional 54,697 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in shares of AzurRx BioPharma in the second quarter worth about $1,284,000. Hedge funds and other institutional investors own 18.93% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “AzurRx BioPharma (AZRX) Sets New 12-Month Low at $1.87” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/12/06/azurrx-biopharma-azrx-sets-new-12-month-low-at-1-87.html.
About AzurRx BioPharma (NASDAQ:AZRX)
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Featured Story: Return on Investment (ROI)
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.